



Cite this: *Biomater. Sci.*, 2018, **6**, 3318

Tannic acid-loaded mesoporous silica for rapid hemostasis and antibacterial activity†

Chengwei Wang,^{a,b,c} Huayi Zhou,^{a,b} Haoyi Niu,^{a,b} Xiaoyu Ma,^{a,b} Yuan Yuan,^{a,c}  ^{*,a,c} Hua Hong^{*,a,c} and Changsheng Liu^{*,a,b}

Massive blood loss and bacterial infection are major challenges for global public health. In this study, we developed tannic acid (TA)-loaded mesoporous silica (MS) nanoparticles for both hemorrhage control and effective antibacterium *via* covalent conjugation and electrostatic adsorption. The TA-absorbed MS could significantly relieve hemolysis and facilitate blood contact, therefore efficiently promoting protein adhesion and the contact activation pathway of the coagulation cascade with desirable hemostasis. Comparably, with increasing TAs absorption, the bleeding control and antibacterial performance were improved simultaneously, especially for 15TMS. Hemostasis tests demonstrated that the 15TMS could reduce the hemostatic time by 65% both *in vitro* and *in vivo*, with lower blood loss and could exhibit better antibacterial activities against *Staphylococcus aureus* and *Staphylococcus epidermidis* as well as promote wound healing. However, the TAs-loaded MS *via* chemical grafting (15T-g-MS) significantly reduced the surface area of MS, by replacing the Si–OH on the MS, and thus it exhibited worse bleeding control and antibacterial efficacy than 15TMS. Furthermore, all the samples exhibited excellent cell viability. Based on these results, it can be concluded that the 15TMS would be a promising material platform for designing hemostats in more extensive clinical application.

Received 20th July 2018,
Accepted 9th October 2018
DOI: 10.1039/c8bm00837j
rsc.li/biomaterials-science

1. Introduction

Uncontrolled hemorrhage caused by severe trauma is the main cause of deaths that usually occur in transportation accident, surgery, or combat.^{1–3} According to statistics, 15–25% of deaths caused by massive bleeding came from trauma deaths in civilian hospitals and 50% was from combat deaths in the military.^{1,2,4} Additionally, severe trauma is prone to infection, which can impair the natural healing process and even cause life-threatening sepsis.^{5,6} Therefore, it still maintains a challenge to develop more alternative and effective hemostatic materials for the control of hemorrhage and infection.

Some of the inorganic materials, such as mineral zeolite⁷ or kaolin,⁸ have already been used as hemostatic materials in a clinical setting, but patients inevitably suffered from thermal injuries and inflammation because of the highly exothermic nature and poor biodegradability of the materials.^{1,9}

Compared with zeolite, mesoporous silica (MS) possesses similar elements and structure, with highly ordered mesopores and a negatively-charged surface.^{9,10} Meanwhile, MS demonstrated desirable biodegradability and biocompatibility.^{10,11} Over the past years, MS as a hemostatic agent was successfully developed in our lab, and the *in vitro* coagulation results showed that this material could achieve effective hemostasis by initiating the intrinsic pathway^{10,11} and that the hemostatic efficiency of MS was further improved by the granulation process.^{12,13}

Trauma infection is another challenge that is easily encountered in curing and can delay the healing process, and even lead to life-threatening complications.^{14,15} In this sense, an ideal hemostat material should be bacteriostatic and/or bactericidal when applied to the wound.^{5,15,16} Based on this concept, various hemostatic agents were developed by loading a bactericide or antibacterial agent, such as an antibiotic, silver ion, and antibacterial peptide, to inhibit wound infection.^{10,14} Among these, tannic acid (TA), a natural compound present in a variety of plants and fruits, has excellent antibacterial efficiency and has already been approved as a human-use material by the FDA.^{17–19} The molecular structure of TA contains a central carbohydrate (glucose) core, which is esterified by phenols (galloyl group).^{20,21} Although the antibacterial mechanism of TA is not clear yet, the presence of a galloyl group (3,4,5-trihydroxybenzoyl group) is considered as the key

^aKey Laboratory for Ultrafine Materials of Ministry of Education, East China University of Science and Technology, Shanghai 200237, PR China.

E-mail: hhong@ecust.edu.cn, yyuan@ecust.edu.cn, liucs@ecust.edu.cn

^bEngineering Research Center for Biomedical Materials of Ministry of Education, East China University of Science and Technology, Shanghai 200237, China

^cShanghai Wego Biological Technology Co., Ltd, Shanghai 200237, PR China

†Electronic supplementary information (ESI) available. See DOI: 10.1039/c8bm00837j

to its antibacterial activity.²² However, the galloyl group can be easily oxidized in neutral/basic pH,²⁰ and thus may hamper TA antibacterial activity. To solve this issue, different methods have been employed to improve the TA stability and activity.^{20,23} Inspired by the above reports, MS can be used as a carrier for TA loading because of its stable porous structure, high surface areas, and tunable pore sizes.^{24,25} Moreover, TA is also biocompatible toward mammalian cells,²⁶ and has low cost and great availability.²⁷ Furthermore, it could be easily coated on a material surface and bind to proteins, antimutagenics, and antioxidants.^{27,28}

Herein, we endeavored to examine the possibility of utilizing TA-loaded MS as an antibacterial and hemostasis agent. We took advantage of both MS and TA to obtain a highly effective hemostasis *via* covalent conjugation and electrostatic adsorption (Scheme 1). Specifically, MS as the carrier and activator component can provide excellent absorption and an efficient activation of coagulation factors. TA as an antibacterial agent and “molecule glue” can provide excellent antibacterial properties and plasma protein crosslinking. The potential of the compound powder as topical hemostatic agents was evaluated in terms of their morphology, physicochemical properties, *in vitro* antibacterial performance, plasma contact, clotting time, PT, and aPTT, as well as hemostatic efficacy in a rat-tail amputation model of severe extremity hemorrhage *in vivo*. We also confirmed the safety and biocompatibility of the materials *via* live/dead staining and hemolysis examination.

2. Results and discussion

2.1 Preparation of TA-loaded MS

As a comparison, TA was loaded onto MS by chemical grafting and physical absorption, respectively. For chemical grafting, the amino-functionalized MS (MS-NH₂) and TA were mixed in water, linked by glutaraldehyde, and named 15T-g-MS. After grafting, the color of 15T-g-MS changed from white to yellow, which was consistent with the previous reports (Fig. 1A).³² For physical absorption, TA and MS were mixed in water, stirred for the set time, and collected by lyophilizing, and named





Fig. 1 (A) Photograph of the prepared samples. (B) FTIR spectrum of the samples. (C) TG characterization of the samples. (D) Zeta potential of the samples (*, $P < 0.05$).

5TMS/15TMS, where 5 and 15 represent the theoretical percentages of TA loaded on the samples.

The successful functionalization of MS was confirmed by FTIR spectra. As shown in Fig. 1B, MS displayed a typical FTIR spectrum of mesoporous silica. The peaks at 3445 cm⁻¹ and 1634 cm⁻¹ were assigned to vibrations of the hydrogen bond of silanols $n(-\text{Si}-\text{OH})$ and $n(-\text{OH})$ of physisorbed water molecules. The peaks of Si-O-Si asymmetric stretching vibration, symmetric stretching vibration, and bending vibration were observed at 1084, 800, and 465 cm⁻¹. The peak at 972 cm⁻¹ was attributed to $n(-\text{Si}-\text{OH})$ of free silanols.²⁹ In the FTIR spectrum of TA, a characteristic peak at 1716 cm⁻¹ was apparent, due to the stretching vibrations of C=O (carboxylic ester) groups, while the peaks at 1612, 1534, and 1447 cm⁻¹ were consistent with aromatic C-C stretches.^{19,42} For 5TMS/15TMS, the characteristic peaks of TA could be observed at 1716, 1534, and 1447 cm⁻¹, which suggests the successful deposition of TA on the MS nanoparticles. For 15T-g-MS, a peak at 2930 cm⁻¹ appeared, corresponding to $n(-\text{CH}_2-)$ stretching spectra, which was attributed to $n(-\text{CH}_2-)$ of APS (Fig. S1†). After GA linking,



Scheme 1 Schematic diagram for the preparation of TA-loaded samples. (A) TMS prepared by simple physical adsorption. (B) T-g-MS as-synthesized utilizing glutaric dialdehyde to crosslink the amino group of MS-NH₂ and the hydroxyl group of TA.

the same characteristic peaks appeared and were slightly stronger than for physical absorption.

The amounts of TA loaded on the surface of MS were confirmed by TG analysis under airflow. The weight loss from TG curves is demonstrated in Fig. 1C. The weight loss of MS was 3.3% between 20 °C and 118 °C, which was attributed to the loss of absorbed water. Other samples showed two-stage weight losses. The first was between 20 °C and 118 °C with about 6.9%, 8%, and 9.6% weight loss, which correspond to the loss of absorbed and bonded water in 5TMS, 15TMS, and 15T-g-MS, respectively. The second stage ranging from about 240 °C and 600 °C showed 4.6%, 11.2%, and 17.5% weight losses of the samples, respectively. This can be attributed to the oxidative degradation of TA loaded on MS. It has to be noted that part of the weight loss of 15T-g-MS was attributed to the oxidative degradation of APS grafted on MS, which was about 6.0% (Fig. S2†). The amount of TA loaded on MS was about 11.5%, close to the saturated mass grafting percentage of TA, as confirmed by TG (Fig. S2†). The TG analysis supported that a similar TA mass was loaded on MS by physical absorption and chemical grafting.

Then, the electrophoretic mobility analysis was used to measure the surface charge (zeta potential) of the samples (Fig. 1D). It can be observed that the zeta potential of the MS was -16.83 mV. After TA absorption, the zeta potentials of 5TMS and 15TMS were -16.33 mV and -17.93 mV, respectively, with no significant change. For 15T-g-MS, compared with the charge of the amino-functionalized MS (Fig. S3†), the surface charge significantly turned to -19 mV.

Fig. 2 shows the N_2 adsorption/desorption isotherms and pore-size distributions of MS before and after TA was loaded. The samples of MS, 5TMS, and 15TMS revealed typical IV hysteresis loops, indicating rod-like pores in these mesoporous nanoparticles. The sharp capillary condensations in the range of relative pressure of 0.2–0.4 suggested a uniform pore-size distribution. The BET surface areas (S_{BET}) of MS was $767 \text{ m}^2 \text{ g}^{-1}$ and the pore volume (V_{P}) was $0.551 \text{ cm}^3 \text{ g}^{-1}$. Meanwhile, after TA was loaded by physical absorbing, the S_{BET} and V_{P} of 5TMS and 15TMS decreased to $642 \text{ m}^2 \text{ g}^{-1}$ and $0.416 \text{ cm}^3 \text{ g}^{-1}$ as well as $509 \text{ m}^2 \text{ g}^{-1}$ and $0.365 \text{ cm}^3 \text{ g}^{-1}$, respectively (Table 1). Comparatively, the S_{BET} and V_{P} of 15T-g-MS decreased dramatically to $65 \text{ m}^2 \text{ g}^{-1}$ and $0.094 \text{ cm}^3 \text{ g}^{-1}$ (Table 1). We think this might be caused by the closure of MS pores in the process of TA grafting, which was confirmed by TEM (Fig. 3D). The BJH

Table 1 Textural properties of the samples

	BET surface area ($\text{m}^2 \text{ g}^{-1}$)	Pore volume ($\text{cm}^3 \text{ g}^{-1}$)	Pore size (\AA)
MS	767	0.551	36
5TMS	642	0.416	50
15TMS	509	0.365	45
15T-g-MS	65	0.094	231

pore diameter of 15T-g-MS really reflect the gap between the nanoparticles of 15T-g-MS because of the pore seal. From the above results, it can be concluded that there was a decrease in S_{BET} and V_{P} of the samples by both TA physical absorbing and chemical grafting. However, there was a more significant change on 15T-g-MS than on 15TMS. The difference between 15TMS and 15T-g-MS lies in the following respects: first, in the process of TA grafting, whereby MS was first functionalized with APS, which led to a partial decrease of S_{BET} (Fig. S4†); second, the TA grafting layer of 15T-g-MS was more compact than the physical absorbing layer of 15TMS, which was confirmed by TEM (Fig. 3). The TEM results also showed that the loading or grafting of TA did not lead to the change of the ordered degree of MS.

2.2 In vitro TA-release and functionality of BSA

The release profiles of the TA-loaded samples were measured in 0.01 M phosphate-buffered saline (PBS) solution with or without BSA at pH 5.0, 7.4, 9.0. As shown in Fig. 4A, in pure PBS solution, almost 100% TA was released in 5TMS and 15TMS at all pHs in 2 h, while almost no release of TA was observed in 15T-g-MS. In contrast, when the samples were immersed in PBS with BSA at different pHs (Fig. 4B), the release of TA in 5TMS decreased with the increasing pH, reaching 35.6% at pH 5.0, 11.6% at pH 7.4, and 2.3% at pH 9.0 in 24 h, respectively; the releasing percentage of TA in 15TMS exhibited the same trend as that of 5TMS, with about 48.9%, 23.2%, and 10.5% at pH 5.0, 7.4, and 9.0 in 24 h, respectively. But, similar to 15T-g-MS in pure PBS, almost no TA was released from 15T-g-MS within the pH range 5.0–9.0. From the above results, it can be inferred that TA release from 5TMS and 15TMS was pH-dependent in the presence of BSA protein. In acidic pH, the amino group of BSA and hydroxyl group of TAs in NH_3^+ and OH_2^+ forms were closely associated with positive charges, presenting a repulsive force, and causing more TA to be released at pH 5 for 5TMS and 15TMS. With the increase of pH, the protonation weakened, thus the release of TA decreased.³³

The above results indicated that the BSA adsorption layer exerted an effect on TA release at different pHs. To further confirm the function of BSA, all the samples were collected after drug release at different pHs, and observed by TEM, as shown in Fig. 5A–C. The protein corona of MS and 15T-g-MS were not obviously varied with the increase in pH, while for 5TMS and 15TMS, the protein corona significantly increased with the increasing pH. Furthermore, it can be confirmed that




Fig. 2 (A) N_2 adsorption/desorption isotherms of the samples. (B) The corresponding pore-size distribution of the samples.




Fig. 3 Characterization of the samples: (A) MS, (B) 5TMS, (C) 15TMS, (D) 15T-g-MS.




Fig. 4 (A) TA release profile of TMS in pure PBS. (B) TA release profile of TMS in BSA PBS solution. (a) pH 5.0. (b) pH 7.4. (c) pH 9.0.

the protein corona was not evidently changed between samples at pH 5.0, but at pH 7.4 and pH 9.0, the protein corona was significantly improved with the increase in mass loading of TA in the samples. However, 15T-g-MS, with the same mass loading of TA as 15TMS had a slightly smaller

decrease than 15TMS. Meanwhile, the adsorption of BSA was measured by the Bradford method at pH 7.4. As shown in Fig. 5D, the capacity of BSA absorption was increased with the increase in TA loading, and slightly decreased in 15T-g-MS, which was similar to the TEM results at pH 7.4. As mentioned




Fig. 5 TEM characterization of BSA absorption: (A) pH 5.0, (B) pH 7.4, (C) pH 9.0, (a) MS, (b) 5TMS, (c) 15TMS, (d) 15T-g-MS. D Bradford method for BSA absorption (*, $p < 0.05$; ***, $p < 0.001$).

above, the TA grafting layer was relatively compact, and thus the TA molecules were confined to the surface of MS and were difficult to release. Consequently, all of the TA molecules were not available for further interaction with BSA by hydrogel bonds. Comparably, the TA adsorbed onto 15TMS exhibited a better adsorption capacity toward the BSA than the other

groups. It could be concluded that 15TMS could have a great ability to absorb plasma protein.

2.3 Hemolysis and plasma contact efficiency

Hemostat should not cause hemolysis and should provide efficient contact in the treatment of bleeding trauma. Herein,

a hemolysis assay was performed as an easy and trustworthy approach to evaluate blood compatibility of the materials.⁴³ Fig. 6A shows the hemolysis ratios of MS ($25.47 \pm 1.87\%$), 5TMS ($25.47 \pm 1.82\%$), 15TMS ($0.50 \pm 0.41\%$), and 15T-g-MS ($0.49 \pm 0.72\%$), respectively. It was found that TA could decrease the hemolysis ratio of MS. This may be explained by the following reason: as in the previous report, TA easily adhered on the surface of material, and was utilized as a cross-linking agent *via* a layer-by-layer (LbL) assembly.⁴⁴ In this study, TA could easily adhere on the surface of MS, which reduced the contact between MS and RBC, thus decreasing the hemolysis potential of MS.

Contact activation is also an important factor in the process of MS-based hemostatic, thus the contact efficiency of the TA-loaded MS was measured in this study and the results are shown in Fig. 6B. It was found that the contact efficiency of 5TMS, 15TMS, and 15T-g-MS were faster during the contact with plasma than that of pure MS after 10 s. It was noted that only the 15TMS group showed no plasma flowing when the tube was inverted after 60 s. It can be demonstrated that TA loading can accelerate contact efficiency and that the 15TMS group exhibited superior efficiency in stopping plasma flow. TA has a variety of phenolic hydroxyl groups, which can accelerate plasma contact; in other respects, as a protein deposit agent, TA can crosslink with plasma protein by strong physical interaction (hydrogen bond), and form a three-dimensional block to stop plasma flowing. Compared to 5TMS and 15T-g-

MS, 15TMS can release more TA than the other two group, which can lead to more extensive physical crosslinking, which are favorable for fast hemostasis.

2.4 *In vitro* clotting capacity

Contact activation of the blood plasma coagulation cascade by the samples was investigated by aPTT and PT measurements. The experimental results showed that the measured aPTT values of MS, 5TMS, and 15TMS were significantly reduced compared with the negative control, while the aPTT value of 15T-g-MS could not be detected. However, the PT time were not all significantly changed. The great change of 15T-g-MS in aPTT may due to the reduction of the available silanols on the MS surface. As previously reported, MS, in contact with plasma, can lead to the activation of the intrinsic blood coagulation cascade by binding the clotting factor XII to a negatively-charged silanols surface *via* positively charged amino acids in its chain.^{8,45} For 15T-g-MS, the natural silanols on the surface of MS were substituted by an amino group of APS in the first modified process. What is more, silanols were also covered by the grafting of TA layer, and the pores of 15T-g-MS were sealed during the grafting process, obstructing the contact between the natural silanol group and coagulation factors.

Clotting time (CT) is an intuitive method to evaluate a sample's hemostatic property. As shown in Table 2, the clotting times of MS, 5TMS, and 15TMS were significantly shorter than the blank control (680 ± 70 s). The CT of MS was approxi-




Fig. 6 (A) Hemolysis ratio of the samples. (B) Plasma contact efficiency (*, $P < 0.05$; ****, $P < 0.0001$).

Table 2 *In vitro* clotting ability

	Control	MS	5TMS	15TMS	15T-g-MS
Clotting time (s)	$680 \pm 70^{**}$	$336.67 \pm 35.12^{**}$	$280 \pm 50^{**}$	$233.33 \pm 32.15^{**}$	>1200
PT (s)	13.37 ± 0.21	12.3 ± 1.39	13.43 ± 0.51	12.8 ± 0.52	11.57 ± 0.74
aPTT (s)	$24.97 \pm 2.46^{***}$	$13.2 \pm 0.06^{***}$	$13.4 \pm 0.20^{***}$	$13.47 \pm 0.46^{***}$	—

** , $p < 0.01$; *** , $p < 0.001$; significance from the control group.

mately 336.67 ± 35.12 s and that of 5TMS and 15TMS were within 280 ± 50 s and 233.33 ± 32.15 s, respectively, faster than that of MS. But the CT of 15T-g-MS was more than 1200 s. These results were consistent with aPTT. From the above results, it can be seen that the physisorbed group led to a significant CT decrease. This phenomenon should be related to the quick contact with blood of the TMS and a rapid TA molecular diffusion into blood and then block forming. These results indicate that MS can lead to the activation of the intrinsic blood coagulation cascade.

2.5 Rat-tail amputation

The *in vivo* hemostatic efficiency was investigated by rat-tail amputation. As shown in Fig. 7A, half of the rat-tail was cut, and treated with samples or standard gauze (SG) with manual compression. The bleeding time and blood loss before complete hemostasis in the different groups were recorded (Fig. 7C and D). The bleeding time for the SG-treated group was about 410 ± 14 s, and it was then reduced to 290 ± 28 s when MS was

applied. Specifically, the 5TMS and 15TMS showed a significant reduction, to about 159.5 ± 13 and 123 ± 22 s, respectively, while the 15T-g-MS group was still about 273 ± 26 s, and the TA-treated group was about 190 ± 14 s. The blood loss of SG group was 1.93 ± 0.09 g and for the test groups of MS, 5TMS, 15TMS, 15T-g-MS, and TA, it was 1.52 ± 0.16 g, 1.30 ± 0.21 g, 1.05 ± 0.13 g, 1.42 ± 0.17 g, and 1.22 ± 0.035 g, respectively, demonstrating that the hemostatic efficacy of TMS used as the positive control was prominent.

2.6 Antibacterial property

Here, the antibacterial properties were investigated. Different amounts of samples were co-cultured with bacterial for 6 h, then 10 μ L co-culture media was pipetted on agar plates for another 18–24 h. From Fig. 8, it can be seen that MS had no influence on the growth of *S. aureus* and *S. epidermidis*, while the antibacterial property increased with increasing TA loading. However, 15T-g-MS's antibacterial property decreased significantly. Similar results can be seen in Fig. 9, and it could




Fig. 7 (A) Scheme of the hemostasis trials in the rat tail amputation model. (B) Digital images of the rat tail amputation models when bleeding stopped. (C) Hemostasis time in the rat tail amputation model. (D) Blood loss in the rat amputation model. (*, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$).




Fig. 8 The antibacterial properties images recorded after co-culture 6 h media pipetted on agar plates for 18–24 h. (The numbers in the picture represent the concentration of the sample, unit, mg mL^{-1}).




Fig. 9 Antibacterial activity of TA-loaded MS (**, $p < 0.01$).

be confirmed that 5TMS and 15TMS possessed a 99% kill rate, while 15T-g-MS had a decreased rate at about 88%. According to previous reports, TA has better antibacterial behavior,^{20,22} and affects the expression of proteins involved in the bacterial cell wall/membrane synthesis.⁴⁶ Compared the antibacterial property of 15TMS and 15T-g-MS, the decreasing antibacterial property of 15T-g-MS was because: first, TA was restricted on the surface of MS by chemical bond, which decreased the contact between TA molecules and the bacterial groups; second, in a previous report, it was shown that the hydroxyphenyl group was of great importance against bacterial groups.²² Herein, part of the phenolic hydroxyl groups was consumed in the process of grafting, leading to a weakening of the antibacterial property.

2.7 *In vivo* wound healing

S. aureus infected full-thickness wounds *in vivo* were established to determine the anti-infection and its effect on wound

healing properties. Here, infected wounds without treatment represented the positive control, uninfected wounds without treatment the negative control, and the infected wounds treated with samples the test groups. The image of wounds at different time points was recorded (Fig. 10A), and the wound closure rate was also collected (Fig. 10B). From the images of the wounds at different time points, it can be confirmed that *S. aureus* infected full-thickness wounds were established; on day 5, the sizes of the wounds treated with or without samples showed no significant differences; on day 10, the sizes of 15TMS and 15T-g-MS treated group were distinctly smaller than the other groups; on day 15, the size of MS-treated group were not complete closed. Also, the statistics results of the wound closure rates demonstrated that the TA-containing samples promoted wound closure faster than the uninfected without treatment group, infected without treatment, and infected treated with MS. As a comparison, the TA-treatment group was also tested (Fig. S5[†]), and it could be confirmed that TA promoted wound healing in the earlier stage, but TA slowed up the wound recovering in the later stage. Furthermore, section tissues from the wounds on the rats at day 15 were collected and stained by hematoxylin and eosin (H&E) (Fig. 11). The results demonstrated that the TA-containing group decreased the inflammatory reaction. From the above results, it can be inferred that the TA-containing groups could kill *S. aureus* and promote wound healing. However, the TA-treated group recovered slowly in the later stage. The dosage of the TA-loaded samples and pure TA were different, as mentioned in previous reports that a high TA dosage can inhibit the collagen synthesis and hinder wound healing process,²⁶ which is probably the reason why the TA-treated group recovered slowly in the later stage.




Fig. 10 (A) Photographs of the appearance of different wounds on days 1, 5, 10, and 15 postoperation with the treatment of the samples. (B) The wound closure rate of TA treated on different days postoperation (*, $P < 0.05$; **, $P < 0.01$).




Fig. 11 H&E staining of wound tissue (scale bar: black 200 μm ; white 100 μm . E, epidermis; I, inflammation).





Fig. 12 Live/dead cell assay of samples; the upper panels are the live cells showing green fluorescence and lower panels are dead cells showing red fluorescence. (Scale bar, 100 μm).

2.8 Cell viability

To confirm the cytocompatibility of the samples, a live/dead assay was performed and observed *via* fluorescence microscopy. As shown in Fig. 12, the untreated group exhibited bright green fluorescence, suggesting most cells in the experimental group were alive. Furthermore, the number of dead cells was also

demonstrated, and were considered to be in the normal range. The result confirmed that the samples were safe for cells.

In summary, the results above proved that the adsorption of TA onto MS could integrate the advantages of both materials and provide efficient hemorrhage control and excellent anti-bacterial property. Based on the previous reports and the current study findings here, it could be concluded that the



Scheme 2 Schematic illustration of the TMS hemostasis process. (A) TMS facilitated rapid blood contact, which caused faster water absorption and blood components concentration, simultaneously. Followed by that, a certain amount of TA was released and further crosslinked with plasma protein, together with the activated coagulation factors by the negative-charged TMS, leading to accelerated clot formation. (B) The molecules of TA were released from TMS and exhibited excellent antibacterial properties.

superior hemostasis performance of 15TMS was mainly attributed to the following respects: (1) When 15TMS contacted with the wound site, fast blood contact was first strengthened by the hydrophilicity of the TAs. This process was then reinforced by the fluid absorption of MS and accelerated blood concentration. (2) TA, as a protein deposition agent, could be released from 15TMS and crosslinked with plasma protein, improving the ability of protein absorption of MS, and eventually increasing the probability of coagulation factors activation (Scheme 2). Additionally, the physically absorbed TA could be released from TMS and could kill bacterial groups. Moreover, the full-thickness skin infection wound model confirmed that TMS had the capability of anti-infection and could promote wound healing.

Furthermore, from the perspective of practical costs, the TMS preparation process is simple and time-saving, without enormous energy consumption and usage of expensive chemicals, compared with 15T-g-MS and other current commercial alternatives. Meanwhile, it is easy to achieve large-scale production without professional training. Thus, this study represents a step forward in the development of hemostatic material with immense clinical and commercial potential.

3. Materials and methods

3.1 Materials

Commercially available chemicals were used as received. Tannic acid was purchased from Aladdin Industrial Co. Ltd

(Shanghai China). Cetyltrimethylammonium bromide (CTAB) and tetraethylorthosilicate (TEOS) were purchased from Shanghai Sinopharm Co. Ltd (Shanghai, China) and used for materials preparation. (3-Aminopropyl)-trimethoxysilane (APS) was purchased from Sigma Aldrich Chemicals and adopted as a coupling agent. Deionized water was used throughout this work and all other chemicals were of analytical grade. Standard strains of *Staphylococcus aureus* (*S. aureus*, ATCC 25923) and *Staphylococcus epidermidis* (*S. epidermidis*, ATCC 49134) were purchased from China General Microbiological Culture Collection Center.

3.2 Mesoporous silica synthesis

Ordered mesoporous silica spheres were synthesized by a one-step basic catalyzed self-assembly process. In brief, 1.2 g of CTAB was dissolved in 535 mL water, followed by the addition of 15 mL of concentrated ammonium hydroxide, and the mixture was stirred to clear and heated to 60 °C. Then, 8 mL of TEOS was added slowly to obtain a homogeneous solution, which was stirred vigorously for another 4 h. The product was filtered and washed several times with ethanol and water, and dried at 80 °C overnight. Thereafter, the as-synthesized powder was calcined at 600 °C in air for 6 h at a rate of 1 °C min⁻¹ in order to remove the structure-directing agent completely.

3.3 Tannic acid loading

3.3.1 Physical absorbing. TA-loaded MS was prepared by the following steps. In detail, 1 g of as-synthesized MS powder

was mixed with a certain amount of 0.1 g mL^{-1} TA solution, with adjusting the water volume to 10 mL, and the mixture was then stirred for 6 h. The samples were collected by lyophilizing.

3.3.2 Chemical grafting. First, MS was modified by APS, according to previous reports.^{29–31} Here, 2 g of MS was dispersed in absolute ethanol, followed by the addition of 2 mL of APS, with refluxing overnight at $60 \text{ }^\circ\text{C}$. The product was filtered and washed several times with ethanol, and then dried at $60 \text{ }^\circ\text{C}$.

TA-grafted MS was prepared by the following procedure.³² First, 0.5 g of amino-functionalized MS was dispersed into 20 mL deionized water containing a certain amount of TA under continuous stirring at $37 \text{ }^\circ\text{C}$. After 2 h, 300 μL glutaraldehyde was added into the mixture, which was then stirred overnight at $37 \text{ }^\circ\text{C}$. The product was then collected by centrifugation and washed several times by water. Finally, it was lyophilized and stored in a desiccator.

3.4 Characterization

The ordered mesoporous structure of the samples was confirmed by transmission electron microscopy (TEM, JEM-2100, JEOL, Japan). Surface analysis of MS was performed by N_2 adsorption/desorption measurement on a Micromeritics ASAP2010 sorptometer (Micromeritics, USA). Prior to detection, the sample was degassed at $100 \text{ }^\circ\text{C}$ under vacuum for 4 h. The specific surface area was determined by the Brunauer–Emmett–Teller (BET) method and the pore parameters (pore volume and pore diameter) were obtained from the adsorption branch on the basis of the Barrett–Joyner–Halenda (BJH) model.

The Fourier-transform infrared (FTIR) spectra were obtained using a PerkinElmer System 2000 spectrometer (Nicolet Magma-550 series II, Midac, USA) from KBr pellets at wavelengths ranging from 4000 to 400 cm^{-1} at a resolution of 1 cm^{-1} with an average of 64 scans. Thermogravimetry-differential scanning calorimetry (TG-DSC) thermograms were recorded with a Thermal Analysis (Nicolet Instrument Corporation, Madison, WI, USA).

Electrophoretic mobility measurements were performed to measure the surface charge (zeta potential) of the samples. The electrophoretic mobility assay was adapted from previous reports.^{10,29} The zeta potential was measured as a function of pH by titrating with 0.5 M HCl and NaOH at $25 \text{ }^\circ\text{C}$. The sample was suspended in 0.1 mol L^{-1} of PBS (pH 7.4) and dispersed by sonication. Reverse titrations were performed to ensure chemical stability of the introduced surface function during the measurements.

3.5 *In vitro* TA-release study and protein absorption

The TA-release profile was measured according to a previous report.¹⁹ Briefly, the experiment was carried out by adding dried sample to 10 mL of the phosphate buffer solution (PBS, 0.1 mol L^{-1}) at different pH with or without BSA protein. This mixture was shaken in a rolling incubator (Kylin-Bell Lab Instruments Co., Ltd, Haimen) under room temperature and

the released concentration as a function of time was analyzed by UV-visible spectroscopy at 285 nm in PBS. After that, the sample was collected by centrifugation and re-suspended in absolute ethanol, pipetted on to the copper mesh, and observed by TEM.

The protein absorption was determined by the Bradford method.³³ Briefly, 10 mg of TA loading sample was suspended in 1 mL of $0.2 \text{ wt}\%$ BSA solution (pH = 7.4), then shaken at $37 \text{ }^\circ\text{C}$. After 1 h, the as-prepared supernatant was collected by centrifugation, and reacted with Bradford reagent for 5 min, and the residual BSA in solution was tested using an ultraviolet spectrophotometer at 595 nm . The amount of adsorbed protein (mg mg^{-1}) was calculated according to the following equation:

$$\text{Absorbed BSA}(\text{mg mg}^{-1}) = \frac{C_0 - C_a}{W} V$$

where C_0 and C_a are the BSA concentrations (mg mL^{-1}) before and after adsorption, respectively, W is the weight of the sample (mg), and V is the volume of the BSA solution (mL).

3.6 *In vitro* blood clotting evaluation

3.6.1 Blood collection and related component preparation.

All the blood samples were collected from New Zealand White Rabbit. The whole blood was drawn from a healthy male rabbit into a 3.8% sodium citrated tube with a blood/coagulant ratio of 9 : 1.

Red blood cells (RBCs) were isolated as packed RBCs from centrifugation of citrated whole blood samples at 3000 g for 15 min at room temperature, and washed three times. After cell washing, 200 μL of packed RBCs was diluted to 4 mL with PBS (5% hematocrit).

Platelet poor plasma (PPP) was isolated as the supernatant from the centrifugation of citrated whole blood samples at 3000 g for 15 min at room temperature.

3.6.2 Hemolysis assay. Hemolysis assay was conducted according to previous reports.^{34,35} The RBC suspension was prepared as mentioned above. Briefly, the diluted RBC suspension (0.2 mL) was then mixed with the sample in PBS (0.8 mL) at set concentrations. PBS and water (0.8 mL) were used instead of the sample suspensions as the negative and positive controls, respectively. The mixture was cultivated at $37 \text{ }^\circ\text{C}$ for 1 h, followed by centrifugation (3000 rpm , 5 min), and then the absorbance of the supernatant at 541 nm was measured by UV-visible spectrometry. The percent hemolysis of the RBCs was calculated using the following formula:

$$\text{Percent hemolysis (\%)} = \frac{\text{OD}_{\text{Sample}} - \text{OD}_{\text{Negative control}}}{\text{OD}_{\text{Positive control}} - \text{OD}_{\text{Negative control}}} \times 100\%$$

3.6.3 PT and aPTT. To explore the activation of the material-induced blood plasma coagulation, *in vitro* coagulation assays were performed by determining the aPTT and PT, defined as the activated partial thromboplastin time and prothrombin time, respectively. This experiment was tested by a

semi-automatic coagulation analyzer (MC-2000, Germany). The platelet poor plasma (PPP) was obtained as mentioned above.

APTT tests were performed by mixing 100 μL of aPTT reagent to 100 μL of citrated plasma. After incubation at 37 $^{\circ}\text{C}$ for 3 min, 100 μL of 25 mM CaCl_2 and the sample were added in the test tube immediately and aPTT was measured simultaneously.

PT tests were performed by incubating 50 μL of citrated plasma, 100 μL of PT reagent and samples at 37 $^{\circ}\text{C}$ for 1 min, respectively. Then the PT reagent and sample were added to the plasma in the test tube and PT was measured. The tests for negative control were performed without samples.

3.6.4 Clotting time. The whole blood clotting test was based on the reported literature.^{36–38} A volume of 270 μL citrated blood was pipetted with a total of 30 μL of 0.2 M calcium chloride (CaCl_2), followed by vortexing for 10 s. Then, 150 μL was mixed with pre-weighed sample into 2 ml plastic tube. The rest of the recalcified blood without a sample was used as the control. The tube was inverted every 15 s until the blood aggregates completely ceased to flow.

3.7 Rat-tail amputation

Sprague-Dawley (SD) rats (weight of 200–250 g) were anesthetized by an intraperitoneal injection of 40 mg kg^{-1} sodium pentobarbital. Fifty percent length of the tail was cut by surgical scissors and then placed in air for 15 s to ensure normal blood loss. Subsequently, the wound was covered with 200 mg of sample. The clotting time (s) and blood loss (g) were recorded during the hemostatic process.^{36,39}

3.8 *In vitro* antibacterial assay

3.8.1 Bacteria culture. *S. aureus* and *S. epidermidis* were selected as the bacteria molds. Before the test, *S. aureus* and *S. epidermidis* were inoculated into 5 mL nutrient broth (NB, peptone 1 g, beef extract 0.3 g, NaCl 0.5 g, water 100 mL) medium at 37 $^{\circ}\text{C}$ for about 6–8 h with shaking at 120 rpm, respectively, and the strain colony was accessed by UV-vis spectroscopy (at an optical density of 0.1 at 600 nm for 1×10^8 CFU mL^{-1}).

3.8.2 Antibacterial assay. The antibacterial activities of the samples against *S. aureus* and *S. epidermidis* were determined.⁴⁰ Briefly, 500 μL of bacterial suspension in sterilized normal saline (2×10^5 CFU mL^{-1}) was pipetted into a sterilized plastic tube containing different amounts of sample and 500 μL NB medium, followed by incubation at 37 $^{\circ}\text{C}$ for 6 h. At the end of that time, 10 μL of the co-culture medium was inoculated onto a standard agar culture plate. Furthermore, 100 μL of the co-culture medium pipetted at a concentration of 2 mg mL^{-1} was spread on to plates after a serial 10-fold dilution in normal saline. After further incubation at 37 $^{\circ}\text{C}$ for 18–24 h, the active bacteria were counted. The results were expressed as kill %:

$$\text{Kill\%} = \frac{\text{cell count of control} - \text{survivor count of sample}}{\text{cell count of control}} \times 100\%.$$

3.9 *In vivo* anti-infective and wound-healing experiments

The *in vivo* anti-infective and wound-healing experiments were performed as previously reported with minor revision.⁴¹ Sprague-Dawley (SD) rats (weight of 200–250 g) were anesthetized by an intraperitoneal injection of 40 mg kg^{-1} sodium pentobarbital. After that, four full-thickness skin injures with a round section of dorsal flank skin (10 mm in diameter) were prepared and infected with 100 μL bacteria suspension (*S. aureus*, $\sim 1 \times 10^9$ CFU mL^{-1}) for 24 h. After 24 h, the samples were placed on the surface of the wound. At the same time, an uninfected wound with 10 mm in diameter was utilized as the negative control, and infected wound with 10 mm in diameter was utilized as the positive control. The wound regions were imaged 1, 5, 10, and 15 d postoperation. The rats were sacrificed on days 15 and the wound tissues postoperation were collected and treated with 4% paraformaldehyde solution to fix the samples. The pathological section of the wound tissue was analyzed by H & E staining. Histological images were taken using a microscope (NIKON, CI-S, Japan).

All the above-mentioned experimental animals, including the New Zealand White Rabbits and SD rats, were cared for and treated in accordance with the NIH guidelines for the care and use of laboratory animals (NIH Publication No. 85e23 Rev. 1985) as approved by the Research Center for Laboratory Animal of Shanghai University of Traditional Chinese Medicine.

3.10 Live/dead viability assay of C2C12 cells

Cell viability was determined using live/dead staining. Briefly, C2C12 cells were seeded in a dish at a density of 1×10^5 cells per dish, the incubated at 37 $^{\circ}\text{C}$ with normal growth media (Dulbecco's Modified Eagle's Medium (DMEM) with 0.11 g L^{-1} L-glutamine, 2.2 g L^{-1} sodium bicarbonate, 10% fetal bovine serum, and 2% antibiotics (200 mg mL^{-1} penicillin and 200 mg mL^{-1} streptomycin)) in a 5% CO_2 atmosphere. After incubation for 24 h, the medium was aspirated out and replaced with sample medium suspension (or solution). After another 24 h, the medium of each dish was removed and rinsed 5 times by PBS, stained by a Live/Dead Viability/Cytotoxicity Kit.

3.11 Statistical analysis

All the experimental results are expressed as the mean \pm standard deviation (SD). Statistical difference was analyzed using one-way analysis of variance (ANOVA). A value of $P < 0.05$ was considered to be statistically significant.

4. Conclusions

The aim of this study was to prepare a novel mesoporous silica-matrixed hemostatic with enhanced hemostasis efficiency and antibacterial ability. The prepared 15TMS could not only quickly and effectively absorb fluid but also induced blood concentration. In addition, hemorrhage control *in vitro* and *in vivo* was achieved, which was attributed to MS contact

activation and TA physical crosslinking. Furthermore, TMS showed excellent antibacterial ability and promoted wound healing. More importantly, TMS exhibited excellent biocompatibility; the hemolysis and cytotoxicity of the MS could be neglected after the modification by TA. We are convinced that this study provides an alternative approach for hemorrhage control.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors wish to express their gratitude to the financial supports from the National Natural Science Foundation of China for Innovative Research Groups (No. 51621002), Science and Technology Commission Shanghai Municipality (16441902800), 111 Project (B14018), and the Fundamental Research Funds for the Central Universities (222201718002).

Notes and references

- X. Yang, W. Liu, N. Li, M. Wang, B. Liang, I. Ullah, A. Luis Neve, Y. Feng, H. Chen and C. Shi, *Biomater. Sci.*, 2017, **5**, 2357–2368.
- C. J. Yan, T. H. Yang, S. K. Zhu and H. Wu, *J. Mater. Chem. B*, 2017, **5**, 3697–3705.
- F. Cheng, C. Y. Liu, X. J. Wei, T. S. Yan, H. B. Li, J. M. He and Y. D. Huang, *ACS Sustainable Chem. Eng.*, 2017, **5**, 3819–3828.
- T. A. Ostomel, Q. Shi and G. D. Stucky, *J. Am. Chem. Soc.*, 2006, **128**, 8384–8385.
- R. Liu, L. Dai, C. Si and Z. Zeng, *Carbohydr. Polym.*, 2018, **195**, 63–70.
- S. Pourshahrestani, E. Zeimaran, N. A. Kadri, N. Gargiulo, H. M. Jindal, S. V. Naveen, S. D. Sekaran, T. Kamarul and M. R. Towler, *ACS Appl. Mater. Interfaces*, 2017, **9**, 31381–31392.
- A. M. Behrens, M. J. Sikorski and P. Kofinas, *J. Biomed. Mater. Res., Part A*, 2014, **102**, 4182–4194.
- X. Sun, Z. Tang, M. Pan, Z. Wang, H. Yang and H. Liu, *Carbohydr. Polym.*, 2017, **177**, 135–143.
- Z. Chen, F. Li, C. Liu, J. Guan, X. Hu, G. Du, X. Yao, J. Wu and F. Tian, *J. Mater. Chem. B*, 2016, **4**, 7146–7154.
- C. Dai, Y. Yuan, C. Liu, J. Wei, H. Hong, X. Li and X. Pan, *Biomaterials*, 2009, **30**, 5364–5375.
- C. Dai, C. Liu, J. Wei, H. Hong and Q. Zhao, *Biomaterials*, 2010, **31**, 7620–7630.
- H. Hong, C. W. Wang, Y. Yuan, X. Qu, J. Wei, Z. F. Lin, H. Y. Zhou and C. S. Liu, *RSC Adv.*, 2016, **6**, 78930–78935.
- H. Y. Zhou, C. W. Wang, H. Y. Niu, B. Duan, X. Y. Ma, H. Hong, Y. Yuan and C. S. Liu, *J. Biomed. Nanotechnol.*, 2018, **14**, 649–661.
- Y. Bu, L. Zhang, J. Liu, L. Zhang, T. Li, H. Shen, X. Wang, F. Yang, P. Tang and D. Wu, *ACS Appl. Mater. Interfaces*, 2016, **8**, 12674–12683.
- S. Pourshahrestani, E. Zeimaran, N. A. Kadri, N. Gargiulo, S. Samuel, S. V. Naveen, T. Kamarul and M. R. Towler, *J. Mater. Chem. B*, 2016, **4**, 71–86.
- J. Hoque, B. Bhattacharjee, R. G. Prakash, K. Paramanandham and J. Haldar, *Biomacromolecules*, 2018, **19**, 267–278.
- K. Kim, M. Shin, M. Y. Koh, J. H. Ryu, M. S. Lee, S. Hong and H. Lee, *Adv. Funct. Mater.*, 2015, **25**, 2402–2410.
- M. Shin, K. Kim, W. Shim, J. W. Yang and H. Lee, *ACS Biomater. Sci. Eng.*, 2016, **2**, 687–696.
- N. Ninan, A. Forget, V. P. Shastri, N. H. Voelcker and A. Blencowe, *ACS Appl. Mater. Interfaces*, 2016, **8**, 28511–28521.
- E. Montanari, A. Gennari, M. Pelliccia, C. Gourmel, E. Lallana, P. Matricardi, A. J. McBain and N. Tirelli, *Macromol. Biosci.*, 2016, **16**, 1815–1823.
- A. S. Glaive, T. Modjinou, D. L. Versace, S. Abbad-Andaloussi, P. Dubot, V. Langlois and E. Renard, *ACS Sustainable Chem. Eng.*, 2017, **5**, 2320–2329.
- T. Taguri, T. Tanaka and I. Kouno, *Biol. Pharm. Bull.*, 2004, **27**, 1965–1969.
- D. Payra, M. Naito, Y. Fujii and Y. Nagao, *Chem. Commun.*, 2016, **52**, 312–315.
- L. Pan, J. Liu, Q. He and J. Shi, *Adv. Mater.*, 2014, **26**, 6742–6748.
- Y. Li and J. Shi, *Adv. Mater.*, 2014, **26**, 3176–3205.
- Y. Zheng, Y. Liang, D. Zhang, X. Sun, L. Liang, J. Li and Y.-N. Liu, *ACS Omega*, 2018, **3**, 4766–4775.
- Z. Wang, H. J. Kang, W. Zhang, S. F. Zhang and J. Z. Li, *Appl. Surf. Sci.*, 2017, **401**, 271–282.
- G. Yun, S. Pan, T. Y. Wang, J. Guo, J. J. Richardson and F. Caruso, *Adv. Healthcare Mater.*, 2018, **7**, 1700934.
- C. W. Wang, H. Hong, Z. F. Lin, Y. Yuan, C. S. Liu, X. Y. Ma and X. Y. Cao, *RSC Adv.*, 2015, **5**, 104283–104292.
- A. M. El-Toni, M. A. Habila, M. A. Ibrahim, J. P. Labis and Z. A. Alothman, *Chem. Eng. J.*, 2014, **251**, 441–451.
- Q. Zhang, K. G. Neoh, L. Xu, S. Lu, E. T. Kang, R. Mahendran and E. Chiong, *Langmuir*, 2014, **30**, 6151–6161.
- X. Liu, M. Liang, M. Liu, R. Su, M. Wang, W. Qi and Z. He, *Nanoscale Res. Lett.*, 2016, **11**, 440.
- F. Bazzaz, E. Binaeian, A. Heydarinasab and A. Ghadi, *Adv. Powder Technol.*, 2018, **29**, 1664–1675.
- Y. Zhao, X. Sun, G. Zhang, B. G. Trewyn, I.I. Slowing and V. S. Lin, *ACS Nano*, 2011, **5**, 1366–1375.
- T. Yu, A. Malugin and H. Ghandehari, *ACS Nano*, 2011, **5**, 5717–5728.
- C. Feng, J. Li, G. S. Wu, Y. Z. Mu, M. Kong, C. Q. Jiang, X. J. Cheng, Y. Liu and X. G. Chen, *ACS Appl. Mater. Interfaces*, 2016, **8**, 34234–34243.
- A. K. Gaharwar, R. K. Avery, A. Assmann, A. Paul, G. H. McKinley, A. Khademhosseini and B. D. Olsen, *ACS Nano*, 2014, **8**, 9833–9842.

- 38 R. K. Avery, H. Albadawi, M. Akbari, Y. S. Zhang, M. J. Duggan, D. V. Sahani, B. D. Olsen, A. Khademhosseini and R. Oklu, *Sci. Transl. Med.*, 2016, **8**, 365ra156.
- 39 A. M. Behrens, M. J. Sikorski, T. Li, Z. J. Wu, B. P. Griffith and P. Kofinas, *Acta Biomater.*, 2014, **10**, 701–708.
- 40 J. B. Li, Y. Q. Qiao, Z. H. Ding and X. Y. Liu, *Surf. Coat. Technol.*, 2011, **205**, 5430–5436.
- 41 M. Zhu, P. Liu, H. Shi, Y. Tian, X. Ju, S. Jiang, Z. Li, M. Wu and Z. Niu, *J. Mater. Chem. B*, 2018, **6**, 3884–3893.
- 42 Q. Song, W.-J. Zhao, H.-X. Yin and H.-Z. Lian, *RSC Adv.*, 2015, **5**, 63896–63902.
- 43 Z. H. Chen, F. Li, C. J. Liu, J. Guan, X. Hu, G. Du, X. P. Yao, J. M. Wu and F. Tian, *J. Mater. Chem. B*, 2016, **4**, 7146–7154.
- 44 A. Shukla, J. C. Fang, S. Puranam, F. R. Jensen and P. T. Hammond, *Adv. Mater.*, 2012, **24**, 492–496.
- 45 T. Yoshida, Y. Yoshioka, Y. Morishita, M. Aoyama, S. Tochigi, T. Hirai, K. Tanaka, K. Nagano, H. Kamada, S. Tsunoda, H. Nabeshi, T. Yoshikawa, K. Higashisaka and Y. Tsutsumi, *Nanotechnology*, 2015, **26**, 245101.
- 46 J. A. Curiel, H. Rodriguez, B. de Las Rivas, P. Anglade, F. Baraige, M. Zagorec, M. Champomier-Verges, R. Munoz and F. Lopez de Felipe, *Mol. Nutr. Food Res.*, 2011, **55**, 1454–1465.